More biopharmaceutical companies with strong cash flow will add to their pipelines by acquiring smaller biotech firms, particularly those with products in mid- to late-stage development, analysts predict. The four biotech deals so far this year include Amgen's purchase of Micromet and Celgene's acquisition of Avila Therapeutics, both valued near $1 billion.

Full Story:

Related Summaries